SCHEMBL4071901

SCHEMBL4071901

COc1cc(C)c(C#N)c(Cl)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.67
L3MBTL1 Q9Y468 3/20 0.51
POLB P06746 3/20 0.42
TSHR P16473 2/20 0.42
MAPK1 P28482 1/20 0.42
KDM4E B2RXH2 7/20 0.41
ALDH1A1 P00352 6/20 0.41
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
HPGD P15428 3/20 0.39
GAA P10253 3/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 2/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP2C9 P11712 1/20 0.38
KDM1A O60341 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4067248 0.94 RECQL (0.59) RECQLL3MBTL1POLBTSHRMAPK1
SCHEMBL17164107 0.88 RECQL (0.70) RECQLL3MBTL1POLBTSHRMAPK1
SCHEMBL4073630 0.81 RECQL (0.71) RECQLL3MBTL1POLBTSHRMAPK1
SCHEMBL2911052 0.81 L3MBTL1 (0.48) RECQLL3MBTL1POLBTSHRMAPK1
SCHEMBL2906258 0.81 RECQL (0.45) RECQLL3MBTL1POLBTSHRMAPK1
SCHEMBL5377959 0.80 RECQL (1.00) RECQLPOLBTSHRMAPK1KDM4E
SCHEMBL17164131 0.79 RECQL (0.67) RECQLL3MBTL1POLBTSHRMAPK1
SCHEMBL3828701 0.78 L3MBTL1 (0.54) RECQLL3MBTL1POLBTSHRMAPK1
SCHEMBL29420807 0.77 KDM4E (0.60) RECQLL3MBTL1POLBTSHRMAPK1
SCHEMBL29496331 0.77 L3MBTL1 (0.57) RECQLL3MBTL1POLBTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS KARUNA THERAPEUTICS INC (US) 2026-02-26 US disclosed
US-12421242-B2 Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions Karuna Therapeutics, Inc. (US) 2025-09-23 US disclosed
WO-2025131049-A1 DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES AND USES THEREOF IGNIS THERAPEUTICS (SUZHOU) LIMITED (CN) 2025-06-26 WO disclosed
US-20240336619-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. 2024-10-10 US disclosed
US-20240327390-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2024-10-03 US disclosed
WO-2024130066-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2024-06-20 WO disclosed
WO-2024130064-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2024-06-20 WO disclosed
WO-2024130062-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2024-06-20 WO disclosed
WO-2024130064-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2024-06-20 WO disclosed
WO-2024130066-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2024-06-20 WO disclosed
WO-2018222795-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-12-06 WO disclosed
US-20180346453-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2018-12-06 US disclosed
WO-2018093569-A1 SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-24 WO disclosed
US-20180002331-A1 5,7-Dihydro-Pyrrolo-Pyridine Derivatives PFIZER INC. (US) 2018-01-04 US disclosed
WO-2018002760-A1 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES FOR TREATING NEUROLOGICAL AND NEURODEGENERATIVE DISEASES PFIZER INC. (US) 2018-01-04 WO disclosed
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US disclosed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP disclosed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US disclosed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP disclosed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327390-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS NR0B1, GRK1, GRIN1 RECQL 2070/4885L3MBTL1 2259/4885POLB 1970/4885
US-20180346453-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS NR0B1, GRK1, GRIN1 RECQL 2070/4885L3MBTL1 2259/4885POLB 1970/4885
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same IL5, IL1B, P2RY4 RECQL 3534/4885L3MBTL1 4883/4885POLB 4143/4885
US-20240336619-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CHRM3, CHRM4, CHRM2 RECQL 1342/4885L3MBTL1 4715/4885POLB 4083/4885
US-20180002331-A1 5,7-Dihydro-Pyrrolo-Pyridine Derivatives CHRM1, CHRM5, CHRM2 RECQL 1281/4885L3MBTL1 719/4885POLB 1809/4885
US-12421242-B2 Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions CHRM3, CHRM4, CHRM2 RECQL 1342/4885L3MBTL1 4715/4885POLB 4083/4885
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CHRM3, CHRM2, CHRM1 RECQL 1867/4885L3MBTL1 2918/4885POLB 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.